Blocking the PD-1/PD-L1 pathway has been promising, with randomised phase II and III trials demonstrating improvement of OS in KRAS mutant NSCLC with checkpoint inhibitors compared to standard chemotherapy, as well as a recent meta-analysis reporting an OS improvement with anti-PD-(L)1 agents with or without chemotherapy in KRAS-mutant NSCLC in the first-line setting [37–40]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.